---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000037"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-06-01T13:06:14+00:00"
generated_at: "2026-06-01T13:07:25.569744+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

## Summary
- Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.
- Company planning additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models.
- Evaluating combinations with KRAS G12C inhibitors, pan-RAS inhibitors, and next-generation RAS-targeted agents.
- Full dataset expected to be presented in fall/winter 2026.
- CEO states belief that pelareorep may serve as immune-priming backbone for next-generation targeted therapies.

## SEC filing metadata
- accession: 0001129928-26-000037
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-06-01T13:06:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/0001129928-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/oncy-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000037
- JSON: https://secwatch.observer/filing/0001129928-26-000037.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.